HETEROLOGOUS EXPRESSION OF HUMAN MICROSOMAL EPOXIDE HYDROLASE IN SACCHAROMYCES-CEREVISIAE - STUDY OF THE VALPROMIDE CARBAMAZEPINE EPOXIDE INTERACTION

被引:22
作者
EUGSTER, HP
SENGSTAG, C
HINNEN, A
MEYER, UA
WURGLER, FE
机构
[1] UNIV BASEL,BIOCTR,DEPT PHARMACOL,CH-4056 BASEL,SWITZERLAND
[2] CIBA GEIGY AG,DEPT BIOTECHNOL,CH-4002 BASEL,SWITZERLAND
关键词
D O I
10.1016/0006-2952(91)90447-D
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A cDNA of human microsomal epoxide hydrolase (hmEH) was constitutively and inducibly expressed in Saccharomyces cerevisiae. The heterologous enzyme was located mainly in the microsomal fraction of yeast cells. Yeast microsomes containing hmEH exerted styrene oxide hydrolase activity (K(m) = 300-mu-M; V(max) = 22 nmol/mg min) as well as carbamazepine epoxide hydrolase activity. The hmEH catalysed exclusively the formation of carbamazepine-10,11-transdihydrodiol, since no carbamazepine-10,11-cisdihydrodiol was detected. Inhibition studies using these microsomes revealed unequivocally hmEH as the target for inhibition by the antiepileptic drug valpromide. A K(i) value of 27-mu-M was determined for the inhibitor valpromide with styrene oxide as substrate. For carbamazepine epoxide, a K(i) value of 8.6-mu-M was obtained, which is well in line with data published for hmEH determined with human liver microsomes. Our results demonstrate the potential of heterologous gene expression in S. cerevisiae and its application to the in vitro study of pharmacological and toxicological problems.
引用
收藏
页码:1367 / 1372
页数:6
相关论文
共 37 条
[21]  
MINAMI M, 1987, J BIOL CHEM, V262, P13837
[22]   RADIOMETRIC ASSAY FOR HEPATIC EPOXIDE HYDRASE ACTIVITY WITH [7-H-3] STYRENE OXIDE [J].
OESCH, F ;
JERINA, DM ;
DALY, J .
BIOCHIMICA ET BIOPHYSICA ACTA, 1971, 227 (03) :685-&
[23]  
PACIFICI GM, 1983, J PHARMACOL EXP THER, V226, P869
[24]   VALPROMIDE INHIBITS HUMAN EPOXIDE HYDROLASE [J].
PACIFICI, GM ;
FRANCHI, M ;
BENCINI, C ;
RANE, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (03) :269-274
[25]   EFFECTS OF VALPROMIDE AND VILOXAZINE ON THE ELIMINATION OF CARBAMAZEPINE-10,11-EPOXIDE, AN ACTIVE METABOLITE OF CARBAMAZEPINE [J].
PERUCCA, E ;
PISANI, F ;
SPINA, E ;
OTERI, G ;
FAZIO, A ;
BERTILSSON, L .
PHARMACOLOGICAL RESEARCH, 1989, 21 (01) :111-112
[26]   EFFECT OF VALPROMIDE ON THE PHARMACOKINETICS OF CARBAMAZEPINE-10, 11-EPOXIDE [J].
PISANI, F ;
FAZIO, A ;
OTERI, G ;
SPINA, E ;
PERUCCA, E ;
BERTILSSON, L .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 25 (05) :611-613
[27]   SODIUM VALPROATE AND VALPROMIDE - DIFFERENTIAL INTERACTIONS WITH CARBAMAZEPINE IN EPILEPTIC PATIENTS [J].
PISANI, F ;
FAZIO, A ;
OTERI, G ;
RUELLO, C ;
GITTO, C ;
RUSSO, F ;
PERUCCA, E .
EPILEPSIA, 1986, 27 (05) :548-552
[28]  
PISANI F, 1981, J PHARM PHARMACOL, V34, P45
[29]   COMPLEMENTARY-DNA AND AMINO-ACID-SEQUENCE OF RAT-LIVER MICROSOMAL, XENOBIOTIC EPOXIDE HYDROLASE [J].
PORTER, TD ;
BECK, TW ;
KASPER, CB .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1986, 248 (01) :121-129
[30]   MICROSOMAL EPOXIDE HYDROLASE PROPERTIES, REGULATION AND FUNCTION [J].
SEIDEGARD, J ;
DEPIERRE, JW .
BIOCHIMICA ET BIOPHYSICA ACTA, 1983, 695 (3-4) :251-270